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recruited to date, and two have been infused with VSTs at
5x10E6 cells/m2/dose. The manufactured VSTs had a CD4+ T-
cell predominance with detectable antiviral activity against
CMV pp65/IE1, EBV-LMP2/EBNA1, and Adv-Hexon/Penton
epitopes based on IFN-g ELISpot assays. All VSTs were non-
alloreactive in chromium release assays utilizing allogeneic
PHA blasts as targets (<5% lysis at effector:target ratios of
20:1). The ﬁrst patient was treated for CMV viremia which
was refractory to ganciclovir and foscarnet following hap-
loidentical HSCT for SCID. Following two VST infusions, the
CMV load reduced from >1,000,000 to<1000 copies/ml. The
second patient was treated for CMV viremia after matched
sibling HSCT for MHC-II deﬁciency, and had viral clearance of
CMV within 1-month post-VST infusion. One patient devel-
oped Grade I skin GVHD post VSTs which resolved within 1
week and was associated with the tapering of immune
suppression.
Conclusions: VSTs are safe and effective for control of viral
infections in patients with PIDD following HSCT. We plan
further evaluation of virus-speciﬁc CTL for patients with
PIDD both before and after HSCT.309
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Background: Inherited bone marrow failure syndromes
(IBMFS) include genetic disorders with hematopoietic
cytopenias due to mutations in genes supporting normal
hematopoiesis. Transformation to myeloid leukemia or
myelodysplastic syndrome occurs in 4-25% by adulthood.
Allogeneic hematopoietic cell transplantation (HCT) is cura-
tive but has been largely limited to sibling donor HCT due to
toxicities of alternative donor transplants. The development
of successful HCT strategies is necessary in this setting to
beneﬁt more patients. This includes optimizing transplant
conditioning, reducing mortality, late effects, and GVHD so
HCT can beneﬁt more patients.
Hypothesis: A reduced intensity conditioning regimen (RIC)
and HCT from matched marrow or matched/one-antigen
mismatched cord will result in high overall survival (OS) and
event-free survival (EFS) in patients (<21 years) with IBMFS
(excluding Fanconi Anemia).
Methods: IBMFS patients (3 Diamond-Blackfan Anemia,
1 Congenital Dyserythropoietic Anemia, 1 Shwachman-
Diamond Syndrome, 2 Congenital Amegakaryocytic
Thrombocytopenia, 1 Congenital BM Failure, 1 X-linked
Thrombocytopenia, 1 Severe Congenital Neutropenia, 1 X-
Chromosome Deletion) received alemtuzumab intrave-
nously for 3 days (dose 33 mg if <10kg; 45 mg if >10kg)
(day -21 to -19), ﬂudarabine (30 mg/m2/day) (day -8 to -4)
and melphalan (140 mg/m2) on day -3. All received acalcineurin inhibitor as GVHD prophylaxis. Marrow re-
cipients received short course methotrexate and steroids,
and cord recipients received mycophenolate.
Results: Eleven patients between 2 months and 14 years of
age (median 23 months) underwent HCT. Nine were from
unrelated donors; ten received BM; one received UCB. Ten
had full donor chimerism by 30 days. OS and EFS were 82%
with median follow up of 62 months (range 12-186). Two
deaths (BM recipients for DBA and Congenital BMF) at day 45
and 346 were due to aGVHD and graft rejection followed by
mortality after a second transplant respectively. The cumu-
lative incidence of acute (grade II-IV) and chronic GVHD was
9 and 0% respectively. Eight of the 9 survivors had success-
fully discontinued systemic immunosuppression by one year
post HCT. Robust immune reconstitution was noted at 1 year
in survivors.
Conclusions: This RIC regimen was tolerated well by this
very young recipient group. The regimen had a high success
rate (also previously described in HCT for Shwachman-Dia-
mond syndrome: Bhatla, BMT 2008) and is expected to have
fewer late toxicities. Though the numbers are small, out-
comes are encouraging in these rare disorders supporting a
HCT consideration early during the course of the disease
prior to marrow related complications.310
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Overview: BK viremia (BKV) occurs in >15% of patients after
hematopoietic cell transplantation (HCT), primarily in asso-
ciation with cystitis. It is unknown if BK virus-induced renal
disease (polyomavirus nephropathy, PVN) is also common
after HCT. Kidney biopsy is the gold standard for the diag-
nosis of PVN but has a high risk of bleeding after HCT. The
non-invasive urinary PV-Haufen test is sensitive/speciﬁc for
PVN in renal transplant recipients with positive/negative
predictive values >90%. PV-Haufen are cast-like BK aggre-
gates that form in virally injured kidney tubules, are shed,
and can easily be detected in urine samples. PV-Haufen do
not form in the bladder and are not seen in cystitis without
PVN. In this pilot study, we used the PV-Haufen test for the
ﬁrst time in children after HCT to screen for PVN.
Methods: Subjects with BKV (potential cases) and without
BKV (presumed controls) after allogeneic HCT were selected
from cohorts at Cincinnati Children’s Hospital and the Chil-
dren’s Hospital of Philadelphia. Urine samples (10-25 ml)
were ﬁxed in a 1:1 ratio with 4% paraformaldehyde, stored at
4C, and tested for urinary PV-Haufen using negative staining
electron microscopy (JASN, 2009, 20(2):416-27). Urine sam-
ples containing 1 PV-Haufen were classiﬁed as positive,
supporting a diagnosis of PVN.
Results:We tested 20 voided urine samples from 15 subjects
(median age 11.5 years, range 5.2-29.8; median HCT follow
up time 306 days, range 87-815). Urine Haufen (Fig 1) were
Haufen+(n¼4) Haufen- (n¼9) p-value*
Peak BKV
after HCT
(copies/mL)
1,255,140
[144,512-1,900,000,000]
1,173,953
[1537-6,000,000]
0.44
Hemorrhagic
cystitis
3 (75%) 6 (67%) 1.00
Dialysis 3 (75%) 0 (0%) 0.01
Death 3 (75%) 2 (22%) 0.22
Data shown as median [IQR] or n (%).
*Wilcoxon rank-sum or Fisher’s exact. Urine samples from 2/15 tested
subjects could not be evaluated.
Figure 1. By routine electron microscopy, a large polyomavirus Haufen cast is
detected in the urine of a hematopoietic cell transplant recipient.
Figure 2. Kidney autopsy specimen from a hematopoietic cell transplant
recipient with detectable urine Haufen. Tissue stained for BK virus using DNA
in situ hybridization. Although the tissue is autolyzed, kidney tubules (arrow
head) and tubular lumens (arrow) show positive staining for BK virus infected
cells,deﬁning polyomavirus nephropathy.
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including one subject with autopsy conﬁrmed PVN (Fig 2).
The table shows associations between urinary PV-Haufen,
peak BKV, and clinical outcomes after HCT.
Conclusions: We provide pilot data potentially indicating a
high risk of PVN after HCT. PV-Haufen were associated with
kidney injury requiring renal replacement therapy and may
thus serve as a non-invasive test to identify patients with
BKV who are at high risk for PVN. More research is needed
including longitudinal follow-up, careful monitoring of renalfunction, and correlation of urinary PV-Haufen data with
BKV and tissue ﬁndings, when available.311
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No prospective or retrospective studies have aimed to
determine the utility, appropriate timing, or health care
utilization (HCU) associated with routine bone marrow (BM)
and cerebrospinal ﬂuid (CSF) analysis following AlloHCT in
children with leukemia.
We conducted a national survey of 62 pediatric bone
marrow transplant practitioners regarding their use of
routine BM/CSF analysis post-AlloHCT. For acute lympho-
blastic leukemia (ALL) patients, 41 physicians (66%) re-
ported performing routine BM analysis in all such patients;
15 (24%) in some patients; and 6 (10%) in no patients. For
acute myeloid leukemia (AML), 39 (63%) reported doing so
in all patients; 9 (14%) in some patients; and 14 (23%) in no
patients.
No standard exists dictating the proper timing or frequency
of screening. For ALL, 11 physicians (24%) reported per-
forming one BM biopsy in the ﬁrst year, 11 (24%) perform
two, 6 (13%) perform three, 12 (27%) perform four, and 5
(12%) perform 5-10. The most common time points to
perform such screening were day 90-100 and day 365. Data
were similar for AML.
The practice of performing routine CSF analysis is even more
varied. Eleven physicians (18%) reported doing so in all post-
AlloHCT ALL patients; 28 (45%) in no such patients; and 23
(37%) only in previously CNS-positive patients. In AML pa-
tients, most practitioners do not perform routine CSF anal-
ysis. Routine usage of intra-thecal chemotherapy is variable
as well.
We also performed a retrospective chart review of 108 pa-
tients who underwent BM/CSF analysis at routine intervals
following AlloHCT at our center. There were 41 relapses with
a median time to relapse of 171 days. Five of these relapses
occurred after day 365. Of the 41 relapses, 11 (27%) were
identiﬁed by routine screening procedures (10 by BM, 1 by
CSF). All relapses identiﬁed by routine surveillance were
detected before day 365.
Thirty-eight patients had routine day 365 BM analyses; zero
of 38 had evidence of relapse. Of these,13 had ALL and 25 had
AML (median age 11 years); median WBC count was 5.8 x
109/L (range 1.8 to 15.6); median platelet count was 173 x
109/L (range 36 to 424); mean peripheral blood chimerism
was 96.9% donor.
With the ultimate goal of reducing HCU, we analyzed pro-
cedure charges and time data. Median charges associated
with routine BM/CSF analysis amounted to $6,613. Median
time spent by families and physicians in the procedure suite
was 3 hours and 34 minutes, respectively.
This data conﬁrms a lack of consensus regarding routine BM/
CSF relapse surveillance following AlloHCT in children with
leukemia. We documented a questionable yield from this
surveillance with an associated high health care utilization.
Therefore, the utility of these routine procedures at day 365
may not be sufﬁciently high to justify their continued routine
